- Home
- LPG vs PHVS Comparison
LPG vs PHVS Comparison
Compare LPG & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPG | PHVS |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LPG | PHVS |
|---|---|---|
| Price | $31.77 | $26.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $35.00 | ★ $40.70 |
| AVG Volume (30 Days) | ★ 544.5K | 101.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | ★ $353,341,476.00 | N/A |
| Revenue This Year | $33.36 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.66 | $11.51 |
| 52 Week High | $38.40 | $29.80 |
Technical Indicators
Market Signals| Indicator | LPG | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 46.56 | 51.12 |
| Support Level | $24.48 | $24.25 |
| Resistance Level | $32.24 | $28.90 |
| Average True Range (ATR) | 1.28 | 1.21 |
| MACD | -0.81 | -0.06 |
| Stochastic Oscillator | 31.16 | 54.90 |
Price Performance
Historical ComparisonAbout LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.